Terray Therapeutics CEO Jacob Berlin (L) and CFO/COO Eli Berlin
October 17, 2024 07:30 AM EDTUpdated 11:39 AM
Financing
AI

Ex­clu­sive: Ter­ray rais­es $120M for its AI ways of de­sign­ing mol­e­cules

Andrew Dunn

Senior Biopharma Correspondent

Ter­ray Ther­a­peu­tics has raised a $120 mil­lion Se­ries B round, aim­ing to get its first drug can­di­date in­to the clin­ic while ad­vanc­ing in its AI …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times